Replies to post #13353 on Mast Therapeutics, Inc. (MSTX)

[lux1]

Target price vs. sales in SCD
Some analysts say that the sales of vepoloxamer in SCD could be in the range of $300-800 million per year.
the Price/Sales ratio or P/S in healthcare sector is a number between 3 to 20. 3 for big company, 20 for small company.
Also if you suppose a P/S very conservati of 5 you have a market capitalisation in the range of $1.5-4 billion.
This market cap. gives a pps in the range $8-$23 share.

[okaly]

Promised I'd keep it real... That's about as real as it gets